HRP20200567T1 - Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon - Google Patents
Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon Download PDFInfo
- Publication number
- HRP20200567T1 HRP20200567T1 HRP20200567TT HRP20200567T HRP20200567T1 HR P20200567 T1 HRP20200567 T1 HR P20200567T1 HR P20200567T T HRP20200567T T HR P20200567TT HR P20200567 T HRP20200567 T HR P20200567T HR P20200567 T1 HRP20200567 T1 HR P20200567T1
- Authority
- HR
- Croatia
- Prior art keywords
- volume
- amount ranging
- weight
- injectable pharmaceutical
- pharmaceutical preparation
- Prior art date
Links
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 title claims 6
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 title claims 4
- 229960003305 alfaxalone Drugs 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 16
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims 14
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 12
- 239000002904 solvent Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims 8
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims 8
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 8
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 8
- 238000002360 preparation method Methods 0.000 claims 8
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 8
- 229960002242 chlorocresol Drugs 0.000 claims 7
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 6
- 229960001950 benzethonium chloride Drugs 0.000 claims 6
- 235000011187 glycerol Nutrition 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 5
- 239000003755 preservative agent Substances 0.000 claims 5
- 230000002335 preservative effect Effects 0.000 claims 5
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 229960000686 benzalkonium chloride Drugs 0.000 claims 4
- 235000019445 benzyl alcohol Nutrition 0.000 claims 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 4
- 239000004327 boric acid Substances 0.000 claims 4
- 229940067596 butylparaben Drugs 0.000 claims 4
- 229960004926 chlorobutanol Drugs 0.000 claims 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims 4
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 4
- 229960002216 methylparaben Drugs 0.000 claims 4
- 229960005323 phenoxyethanol Drugs 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 4
- 229960003415 propylparaben Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 239000000337 buffer salt Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Injektabilni farmaceutski pripravak, naznačen time, da sadrži:
vodu;
jedan ili više kompleksa topivih u vodi, svaki koji sadrži 2-hidroksipropil-β-ciklodekstrin i alfaksalon;
opcionalno pufer učinkovit u osiguravanju pH u pripravku u rasponu od 4.0 do 9.0;
najmanje jedan prezervativ, gdje se najmanje jedan prezervativ bira iz skupine koja se sastoji od:
metilparabena, etilparabena, propilparabena, butilparabena, ili njihovih soli, ili benzetonij klorida u količini u rasponu od 0,005 do 1 % težina/volumen;
m-krezola, ili klorokrezola, u količini u rasponu od 0,1 do 1 % težina/volumen;
feniletanola ili fenoksietanola u količini u rasponu od 0,1 do 1 % težina/volumen;
klorobutanola ili fenola u količini u rasponu od 0,05 do 1 % težina/volumen;
borne kiseline, u količini u rasponu od 0,25 do 5 % težina/volumen;
benzilnog alkohola u količini u rasponu od 0,1 do 5 % težina/volumen;
benzalkonijevog klorida u količini u rasponu od 0,001 do 1 % težina/volumen;
i njihovih mješavina; i
najmanje jednog dodatnog otapala u količini u rasponu od 1 do 30 % težina/volumen odabrane iz skupine koja se sastoji od etanola, glicerina, izopropilnog alkohola, polietilen glikola i njihovih mješavina.
2. Postupak za proizvodnju injektabilnog farmaceutskog pripravka, naznačen time, da postupak obuhvaća:
pripravu prvog pripravka na način da se:
a) 2-hidroksipropil-β-ciklodekstrin otopi u vodi kako bi se dobila otopina;
b) u otopinu dodaje alfakson;
c) opcionalno dodaje dodatna voda kako bi se 2-hidroksipropil-β-ciklodekstrin otopio u potpunosti;
d) opcionalno dodaju puferske soli;
e) opcionalno podešava pH;
pripravu drugog pripravka na način da se:
otopi najmanje jedan prezervativ u jednom ili više dodatnih otapala, gdje se najmanje jedan prezervativ bira iz skupine koja se sastoji od:
metilparabena, etilparabena, propilparabena, butilparabena, ili njihovih soli, ili benzetonij klorida u količini u rasponu od 0,005 do 1 % težina/volumen;
m-krezola, ili klorokrezola, u količini u rasponu od 0,1 do 1 % težina/volumen;
feniletanola ili fenoksietanola u količini u rasponu od 0,1 do 1 % težina/volumen;
klorobutanola ili fenola u količini u rasponu od 0,05 do 1 % težina/volumen;
borne kiseline, u količini u rasponu od 0,25 do 5 % težina/volumen;
benzilnog alkohola u količini u rasponu od 0,1 do 5 % težina/volumen;
benzalkonijevog klorida u količini u rasponu od 0,001 do 1 % težina/volumen;
i njihovih mješavina; i
najmanje jednog dodatnog otapala u količini u rasponu od 1 do 30 % težina/volumen odabrane iz skupine koja se sastoji od etanola, glicerina, izopropilnog alkohola, polietilen glikola i njihovih mješavina;
i dobivanje injektabilnog farmaceutskog pripravka na način da se:
a) spoje prvi i drugi pripravci;
b) opcionalno doda dodatna voda kako bi se spojeni pripravak doveo do željenog volumena; i
c) sterilizira spojeni pripravak.
3. Postupak za čuvanje injektabilnog farmaceutskog pripravka koji sadrži vodu;
jedan ili više kompleksa topivih u vodi, svaki koji sadrži 2-hidroksipropil-β-ciklodekstrin i alfaksalon; i
opcionalno pufer učinkovit za osiguravanje pH u pripravku u rasponu od 4.0 do 9.0;
naznačen time, da
se dodaje učinkovita količina najmanje jednog prezervativa i najmanje jednog dodatnog otapala, gdje se najmanje jedan prezervativ bira iz skupine koja se sastoji od:
metilparabena, etilparabena, propilparabena, butilparabena, ili njihovih soli, ili benzetonij klorida u količini u rasponu od 0,005 do 1 % težina/volumen;
m-krezola, ili klorokrezola, u količini u rasponu od 0,1 do 1 % težina/volumen;
feniletanola ili fenoksietanola u količini u rasponu od 0,1 do 1 % težina/volumen;
klorobutanola ili fenola u količini u rasponu od 0,05 do 1 % težina/volumen;
borne kiseline, u količini u rasponu od 0,25 do 5 % težina/volumen;
benzilnog alkohola u količini u rasponu od 0,1 do 5 % težina/volumen;
benzalkonijevog klorida u količini u rasponu od 0,001 do 1 % težina/volumen;
i njihovih mješavina; i
najmanje jednog dodatnog otapala u količini u rasponu od 1 do 30 % težina/volumen odabrane iz skupine koja se sastoji od etanola, glicerina, izopropilnog alkohola, polietilen glikola i njihovih mješavina.
4. Uporaba najmanje jednog dodatnog otapala i najmanje jednog prezervativa naznačena time, da se čuva injektabilni farmaceutski pripravak koji sadrži
vodu;
jedan ili više kompleksa topivih u vodi, svaki koji sadrži 2-hidroksipropil-β-ciklodekstrin i alfaksalon; i
opcionalno pufer učinkovit za dobivanje pH u pripravku u rasponu od 4.0 do 9.0;
gdje se dodaje učinkovita količina najmanje jednog prezervativa i najmanje jednog dodatnog otapala, gdje se najmanje jedan prezervativ bira iz skupine koja se sastoji od:
metilparabena, etilparabena, propilparabena, butilparabena, ili njihovih soli, ili benzetonij klorida u količini u rasponu od 0,005 do 1 % težina/volumen;
m-krezola, ili klorokrezola, u količini u rasponu od 0,1 do 1 % težina/volumen;
feniletanola ili fenoksietanola u količini u rasponu od 0,1 do 1 % težina/volumen;
klorobutanola ili fenola u količini u rasponu od 0,05 do 1 % težina/volumen;
borne kiseline, u količini u rasponu od 0,25 do 5 % težina/volumen;
benzilnog alkohola u količini u rasponu od 0,1 do 5 % težina/volumen;
benzalkonijevog klorida u količini u rasponu od 0,001 do 1 % težina/volumen;
ili njihovih mješavina; i
najmanje jednog dodatnog otapala u količini u rasponu od 1 do 30 % težina/volumen odabrane iz skupine koja se sastoji od: etanola, glicerina, izopropilnog alkohola, polietilen glikola i njihovih mješavina.
5. Injektabilni farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time, da je za uporabu u liječenju boli ili upale.
6. Injektabilni farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time, da je za uporabu u postupku anestezije.
7. Injektabilni farmaceutski pripravak prema patentnom zahtjevu 1, postupak za čuvanje injektabilnog farmaceutskog pripravka prema patentnom zahtjevu 2, uporaba najmanje jednog prezervativa prema patentnom zahtjevu 4, injektabilni farmaceutski pripravak za uporabu prema patentnom zahtjevu 5 ili patentnom zahtjevu 6, naznačeni time, da se najmanje jedno dodatno otapalo odabire iz skupine koja se sastoji od: etanola, glicerina, i njihovih mješavina.
8. Injektabilni farmaceutski pripravak prema patentnom zahtjevu 1, postupak za čuvanje injektabilnog farmaceutskog pripravka prema patentnom zahtjevu 2, uporaba najmanje jednog prezervativa prema patentnom zahtjevu 4, injektabilni farmaceutski pripravak za uporabu prema patentnom zahtjevu 5 ili patentnom zahtjevu 6, naznačeni time, da je: najmanje jedno dodatno otapalo etanol.
9. Injektabilni farmaceutski pripravak prema patentnom zahtjevu 1, postupak za čuvanje injektabilnog farmaceutskog pripravka prema patentnom zahtjevu 2, uporaba najmanje jednog prezervativa prema patentnom zahtjevu 4, injektabilni farmaceutski pripravak za uporabu prema patentnom zahtjevu 5 ili patentnom zahtjevu 6, naznačeni time, da se:
najmanje jedan prezervativ odabire iz skupine od: klorokrezol, benzetonij klorid, ili njihovih mješavina.
10. Injektabilni farmaceutski pripravak prema patentnom zahtjevu 1, postupak za čuvanje injektabilnog farmaceutskog pripravka prema patentnom zahtjevu 2, uporaba najmanje jednog prezervativa prema patentnom zahtjevu 4, injektabilni farmaceutski pripravak za uporabu prema patentnom zahtjevu 5 ili patentnom zahtjevu 6, naznačeni time, da je:
najmanje jedno dodatno otapalo etanol, ili mješavina etanola i glicerina; i
da se najmanje jedan prezervativ bira iz skupine koja se sastoji od: klorokrezola, benzetonijevog klorida, ili njihovih mješavina.
11. Injektabilni farmaceutski pripravak prema patentnom zahtjevu 1, postupak za čuvanje injektabilnog farmaceutskog pripravka prema patentnom zahtjevu 2, uporaba najmanje jednog prezervativa prema patentnom zahtjevu 4, injektabilni farmaceutski pripravak za uporabu prema patentnom zahtjevu 5 ili patentnom zahtjevu 6, naznačeni time, da je:
najmanje jedno dodatno otapalo etanol; i
najmanje jedan prezervativ klorokrezol.
12. Injektabilni farmaceutski pripravak prema patentnom zahtjevu 1, postupak za čuvanje injektabilnog farmaceutskog pripravka prema patentnom zahtjevu 2, uporaba najmanje jednog prezervativa prema patentnom zahtjevu 4, injektabilni farmaceutski pripravak za uporabu prema patentnom zahtjevu 5 ili patentnom zahtjevu 6, naznačeni time, da je prisutan pufer učinkovit u stabilizaciji hidrofobnog lijeka i osiguravanju pH pripravka u rasponu od 4.0 do 9.0 i bira se iz skupine koja se sastoji od pufera na osnovu fosfata, na osnovu kiselog fosfata ili na osnovu citrata.
13. Injektabilni farmaceutski pripravak prema patentnom zahtjevu 1, postupak za čuvanje injektabilnog farmaceutskog pripravka prema patentnom zahtjevu 2, uporaba najmanje jednog prezervativa prema patentnom zahtjevu 4, injektabilni farmaceutski pripravak za uporabu prema patentnom zahtjevu 5 ili patentnom zahtjevu 6, naznačeni time, da pripravak nadalje sadrži najmanje jedan hidrofilni lijek.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011904970A AU2011904970A0 (en) | 2011-11-29 | Pharmaceutical compositions | |
AU2012904962A AU2012904962A0 (en) | 2012-11-09 | Pharmaceutical compositions | |
PCT/AU2012/001452 WO2013078500A1 (en) | 2011-11-29 | 2012-11-27 | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
EP12853138.1A EP2785352B1 (en) | 2011-11-29 | 2012-11-27 | Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200567T1 true HRP20200567T1 (hr) | 2020-06-26 |
Family
ID=48534526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200567TT HRP20200567T1 (hr) | 2011-11-29 | 2020-04-07 | Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon |
Country Status (19)
Country | Link |
---|---|
US (4) | US9492552B2 (hr) |
EP (2) | EP3446692A1 (hr) |
JP (2) | JP5819005B2 (hr) |
KR (1) | KR101922752B1 (hr) |
CN (2) | CN103998046B (hr) |
AR (1) | AR089004A1 (hr) |
AU (1) | AU2012268889B2 (hr) |
BR (1) | BR112014012985B1 (hr) |
CA (1) | CA2852716C (hr) |
DK (1) | DK2785352T3 (hr) |
ES (1) | ES2784629T3 (hr) |
HK (1) | HK1198325A1 (hr) |
HR (1) | HRP20200567T1 (hr) |
IL (1) | IL232860B (hr) |
IN (1) | IN2014KN01341A (hr) |
SG (2) | SG11201401597TA (hr) |
TW (1) | TWI552770B (hr) |
WO (1) | WO2013078500A1 (hr) |
ZA (1) | ZA201402895B (hr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013273764B2 (en) * | 2011-11-29 | 2016-05-05 | Zoetis Services Llc | Pharmaceutical compositions |
CN112472814A (zh) | 2012-01-23 | 2021-03-12 | 萨奇治疗股份有限公司 | 神经活性类固醇制剂和治疗中枢神经***障碍的方法 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
RU2652783C2 (ru) | 2012-12-21 | 2018-05-03 | Санофи | Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона |
JP6180241B2 (ja) * | 2013-08-29 | 2017-08-16 | 学校法人同志社 | シクロデキストリン誘導体及び医薬組成物 |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
MX2017011103A (es) * | 2015-04-01 | 2018-05-07 | Int Dioxcide Inc | Composición estabilizada para el control de olor y la deshidratación potenciada combinados. |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
KR101718733B1 (ko) * | 2015-08-21 | 2017-03-22 | 국제약품 주식회사 | 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제 |
NL2015865B1 (en) * | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
CN110215430A (zh) * | 2018-03-02 | 2019-09-10 | 刘力 | 新型可注射的***药物组合物 |
KR102141826B1 (ko) * | 2018-10-05 | 2020-08-07 | 건국대학교 산학협력단 | 양이온성 베타 시클로덱스트린 올리고머를 이용한 외부 pH 자극 반응형 자가치유성 하이드로젤 |
WO2020093256A1 (zh) * | 2018-11-07 | 2020-05-14 | 比卡生物科技(广州)有限公司 | 一种澄清丙泊酚注射液及其制备方法 |
MX2021009777A (es) | 2019-02-15 | 2021-12-15 | Saol Int Development Ltd | Formulaciones inyectables de fenol y metodos de su uso. |
EP3725298A1 (en) | 2019-04-16 | 2020-10-21 | Faes Farma, S.A. | Stable and preserved pharmaceutical compositions of bilastine |
US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
EP3766475A1 (en) | 2019-07-15 | 2021-01-20 | OP-Hygiene IP GmbH | Wipes |
FR3117337B1 (fr) * | 2020-12-10 | 2023-04-28 | Centre Hospitalier Univ De Lille | Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable |
KR20230122271A (ko) | 2022-02-14 | 2023-08-22 | 주식회사 에이아이인사이트 | 파라벤계 보존제의 안정성 증진용 조성물 및 이를 포함하는 보존제 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4728509A (en) | 1985-08-19 | 1988-03-01 | Takeda Chemical Industries, Ltd. | Aqueous liquid preparation |
TW401300B (en) * | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
JPH06293638A (ja) | 1993-04-06 | 1994-10-21 | Lion Corp | 安定なビタミンa類点眼剤 |
ZA962214B (en) * | 1995-04-10 | 1996-10-07 | Farmarc Nederland Bv | Pharmaceutical composition |
JP3934705B2 (ja) | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
TW434023B (en) | 1995-09-18 | 2001-05-16 | Novartis Ag | Preserved ophthalmic composition |
CA2342797A1 (en) | 1998-09-02 | 2000-03-09 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
AUPQ633900A0 (en) | 2000-03-20 | 2000-04-15 | Jurox Pty Ltd | Anaesthetic composition |
IN187686B (hr) * | 2000-06-21 | 2002-06-08 | Bharat Serums & Vaccines Ltd | |
US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
JP2003089632A (ja) | 2001-09-17 | 2003-03-28 | Otsuka Pharmaceut Factory Inc | 注射用水性製剤 |
US20050239746A1 (en) * | 2002-02-01 | 2005-10-27 | Penkler Lawrence J | Pharmaceutical composition |
US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
US20040053895A1 (en) * | 2002-09-18 | 2004-03-18 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
JP4275394B2 (ja) | 2002-12-05 | 2009-06-10 | 株式会社大塚製薬工場 | 注射用シロスタゾール水性製剤 |
US8183230B2 (en) | 2004-01-30 | 2012-05-22 | Pfizer Inc. | Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms |
US6969706B1 (en) * | 2004-05-12 | 2005-11-29 | Allergan, Inc. | Preserved pharmaceutical compositions comprising cyclodextrins |
JP5577021B2 (ja) | 2005-02-17 | 2014-08-20 | アボット・ラボラトリーズ | 動物における障害を治療および予防するための薬剤組成物の経粘膜投与 |
CN101360503A (zh) | 2005-11-18 | 2009-02-04 | 阿斯利康公司 | 液体制剂 |
AU2009314072C1 (en) * | 2008-11-15 | 2016-11-10 | Melinta Subsidiary Corp. | Antimicrobial compositions |
SG181997A1 (en) * | 2010-01-21 | 2012-08-30 | Goodchild Invest Pty Ltd | Anaesthetic formulation |
-
2012
- 2012-11-27 AU AU2012268889A patent/AU2012268889B2/en active Active
- 2012-11-27 US US14/361,677 patent/US9492552B2/en active Active
- 2012-11-27 CN CN201280058592.1A patent/CN103998046B/zh active Active
- 2012-11-27 SG SG11201401597TA patent/SG11201401597TA/en unknown
- 2012-11-27 DK DK12853138.1T patent/DK2785352T3/da active
- 2012-11-27 EP EP18198778.5A patent/EP3446692A1/en not_active Withdrawn
- 2012-11-27 ES ES12853138T patent/ES2784629T3/es active Active
- 2012-11-27 BR BR112014012985-1A patent/BR112014012985B1/pt active IP Right Grant
- 2012-11-27 CA CA2852716A patent/CA2852716C/en active Active
- 2012-11-27 IN IN1341KON2014 patent/IN2014KN01341A/en unknown
- 2012-11-27 EP EP12853138.1A patent/EP2785352B1/en active Active
- 2012-11-27 KR KR1020147010730A patent/KR101922752B1/ko active IP Right Grant
- 2012-11-27 CN CN201710259261.9A patent/CN107261152B/zh active Active
- 2012-11-27 SG SG10201506273PA patent/SG10201506273PA/en unknown
- 2012-11-27 WO PCT/AU2012/001452 patent/WO2013078500A1/en active Application Filing
- 2012-11-27 JP JP2014542644A patent/JP5819005B2/ja active Active
- 2012-11-28 AR ARP120104457A patent/AR089004A1/es not_active Application Discontinuation
- 2012-11-29 TW TW101144782A patent/TWI552770B/zh active
-
2014
- 2014-04-22 ZA ZA2014/02895A patent/ZA201402895B/en unknown
- 2014-05-28 IL IL23286014A patent/IL232860B/en active IP Right Grant
- 2014-11-24 HK HK14111843.0A patent/HK1198325A1/zh unknown
-
2015
- 2015-02-04 JP JP2015020091A patent/JP6095707B2/ja active Active
-
2016
- 2016-09-29 US US15/280,826 patent/US10188664B2/en active Active
-
2018
- 2018-12-18 US US16/224,433 patent/US20190125762A1/en active Pending
-
2020
- 2020-04-07 HR HRP20200567TT patent/HRP20200567T1/hr unknown
-
2023
- 2023-05-26 US US18/324,305 patent/US20230293550A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200567T1 (hr) | Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon | |
CY1122838T1 (el) | Τοπικες συνθεσεις οι οποιες περιλαμβανουν φιπρονιλη και περμεθρινη και μεθοδοι χρησης | |
JP2015145364A5 (hr) | ||
HRP20221355T1 (hr) | Liofilizirani pripravak citotoksičnih dipeptida | |
CA2864118A1 (en) | Formulations of bendamustine | |
PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
AR086115A1 (es) | Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas | |
EA023208B1 (ru) | Фармацевтические композиции, которые содержат имидазохинолин(амины) и их производные, пригодные для местного введения | |
RU2015137145A (ru) | Новые жидкие композиции с повышенной стабильностью | |
CO6210803A2 (es) | Formulaciones liquidas formadoras de pelicula dermica para la liberacion de farmaco a la piel | |
WO2011018635A3 (en) | Photosensitizing compositions | |
US20110217360A1 (en) | Octenidine composition | |
EA201190161A1 (ru) | Способ получения твердых лекарственных форм солифенацина и его фармацевтически приемлемых солей для перорального введения | |
HRP20200329T1 (hr) | Poboljšane formulacije levosimendana za intravensku primjenu u obliku infuzije ili injekcije i koncentrata infuzije | |
WO2015198257A1 (en) | Stable carfilzomib injection | |
KR20170036058A (ko) | 코 적용을 위한 시네올-함유 조성물 | |
AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
WO2014178789A9 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
US20190083492A1 (en) | Topical minoxidil composition | |
HRP20140676T1 (hr) | Formulacije deoksikolne kiseline i njezinih soli | |
CA2804477A1 (en) | Stable aqueous formulations comprising poorly water soluble active ingredients | |
BR112015018200A2 (pt) | composição mastigável para administração oral e processo para preparar a mesma | |
GR1008234B (el) | Παρεντερικο σκευασμα ενος αντιμυκητιασικου παραγοντα τριαζολης και μεθοδος για την παρασκευη αυτου | |
HRP20150387T1 (hr) | Sol kolina i trometamina od likofelona | |
WO2015087267A3 (en) | Stable bromfenac ophthalmic solution |